Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

NCT03837808 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

384

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma
Nasopharyngeal Neoplasms
Nasopharyngeal Diseases
Head and Neck Neoplasm

Interventions

DRUG: Nimotuzumab
DRUG: Cisplatin

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]
[object Object]